Drug Discovery@nature.com 15 February 2013

Advertisement Please visit PBL InterferonSource/ Assay Solutions to find out how we may address your assay development and execution needs in single- and multiplex ELISA, cell based assays, antibody development, protein expression and purification, custom assays, and beyond. For more information, click here. TABLE OF CONTENTS 15 February 2013 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Immunology & Cell Biology is proud to present a Special Feature focussing on the interface between mesenchymal stromal cells and the immune system. This contains review articles covering topics that largely focus on the interactions of MSCs with cells of the immune system. Further background information is available through the accompanying web focus which links to related articles from across NPG. Access the Special Feature and Web Focus on MSCs today!   News Top Small-molecule drug drives cancer cells to suicide doi:10.1038/nature.2013.12385 Studies in mice show therapy is effective even in hard-to-treat brain tumours. Full Text Europe bets on drug discovery doi:10.1038/494020a Proponents hope consortium will revive flagging industry. Full Text Amgen deal triggers watchful waiting in targeted nanomedicine doi:10.1038/nm0213-120b Amgen and BIND Biosciences announced a agreement to develop and commercialize an anticancer therapy that combines BIND's nanomedical delivery technology with one of Amgen's targeted kinase inhibitors. Full Text First 'breakthrough' drugs designated, but dilution worries linger doi:10.1038/nbt0213-89 Two drugs for cystic fibrosis receive the first 'breakthrough' designation under a new FDA programme to speed the development of therapies for serious diseases. Full Text Analysis Top 2012 gets a new deal doi:10.1038/scibx.2013.105 SciBX's second annual global analysis of public-private partnerships and early stage venture financing activity reveals that government institutions are taking a significant role in forming and funding PPPs, and California-based companies are leading the way in PPP activity. Full Text Smoking cessation drugs market doi:10.1038/nrd3914 This analysis looks at smoking cessation therapies currently in development, including the novel approach of vaccinating smokers against nicotine. Full Text Research Highlights Top Antibacterial drugs: New antibiotics on the horizon? doi:10.1038/nrd3940 Two recent papers report novel strategies for combating the prevalent bacterial pathogen Staphylococcus aureus. Full Text Neurodegenerative disease: Targeting pre-existing plaques in AD doi:10.1038/nrd3939 Researchers have developed a plaque-specific monoclonal antibody that can clear existing plaques without the side effects seen with other anti-amyloid-β therapeutics in development. Full Text Anticancer drugs: Assault on MALT1 doi:10.1038/nrd3942 Two new studies have identified small-molecule inhibitors of MALT1 that show anticancer activity in vitro and in vivo. Full Text Research & Reviews Top Targeting eosinophils in allergy, inflammation and beyond doi:10.1038/nrd3838 The authors describe recent advances in the development of the first generation of therapies that target eosinophils, as well as emerging strategies. Full Text Advances in targeting cell surface signalling molecules for immune modulation doi:10.1038/nrd3877 This review discusses immunomodulatory signalling pathways that provide targets for therapeutic intervention and the current state of drug development in the field. Full Text Potentiating antibacterial activity by predictably enhancing endogenous microbial ROS production doi:10.1038/nbt.2458 Researchers present a systems-based method to tune ROS production in bacteria and demonstrate that increased microbial ROS production can potentiate killing by oxidants and antibiotics. Full Text Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance doi:10.1038/nm.3056 As expression of this transcriptional regulator is elevated in fat from obese humans, TRIP-Br2 might be a new therapeutic target against insulin resistance and hyperlipidemia. Full Text Drug Discovery JOBS of the week Drug Discovery Opportunities at D. E. Shaw Research D. E. Shaw Research Postdoctoral Research Position in Immunology Washington University School of Medicine R&D S&E Chemistry Research Scientist Sandia National Laboratories Lead Chemist MOF Technologies Polymer Chemist Bioplastech More Science jobs from Drug Discovery EVENT Tumor Imaging in Cancer Drug Development 04.30.13 Boston, US More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.